Lankenau Medical Center

About: Lankenau Medical Center is a healthcare organization based out in Philadelphia, Pennsylvania, United States. It is known for research contribution in the topics: Atrial fibrillation & Medicine. The organization has 436 authors who have published 414 publications receiving 7095 citations. The organization is also known as: Lankenau Hospital.

Zilver PTX peripheral paclitaxel-eluting stent: a technology evaluation.

Abstract: The Zilver PTX stent was the first self-expanding drug-coated stent approved by the United States Food and Drug Administration (US FDA) for use in the superficial femoral artery (SFA) above the kne

Should Local Anesthesia with Conscious Sedation Be Considered the Standard of Care Over General Anesthesia for Transcatheter Aortic Valve Replacement via the Transfemoral Approach

Abstract: A new cardiac surgeon, Dr. Jones, has just been hired by the hospital to begin a transcatheter aortic valve replacement (TAVR) program. Prior to his start date, Dr. Jones requested to meet with the cardiac anesthesia attendings to discuss the feasibility of doing all of the transfemoral TAVR cases using only local anesthesia with conscious sedation (LACS).

Elevated factor VIII: an unfamiliar risk factor for cerebral venous thrombosis.

Abstract: An elevated factor VIII level has been shown to be an independent risk factor for venous thrombosis. However, physicians screen for this factor far less frequently than they screen for other coagulopathies. The causes of increased factor VIII levels are likely a combination of genetic and acquired variables. The authors describe a case of a healthy 48-year-old woman found to have a cerebral venous thrombosis, with her only identifiable risk factor being an elevated factor VIII level.

Transanal Robotic Surgery and Future Directions

Abstract: Transanal surgery draws its roots from transanal endoscopic microsurgery (TEM), invented by Dr. Gerhard Buess in 1983, and the transanal abdominal transanal proctosigmoidectomy (TATA), as described by Dr. Gerald Marks in 1984. Early experience in TEM focused on excision of benign rectal lesions but was later successfully expanded to the treatment of partial thickness rectal cancer. TATA allowed for the radical excision of distal rectal cancer and addressed the difficulties of operating in the narrow pelvis, obtaining a known distal margin in the radiated rectum and allowing for sphincter preservation with the avoidance of a permanent colostomy. Recent evolution in technology has built upon these techniques and allowed total mesorectal excision to be performed entirely transanally. The challenges of transanal surgery have limited its adoption; however, recent advances in robotic surgery, which include novel platforms such as the Flex® Robotic System, STRAS robot, and da Vinci SP Surgical System, promise to broaden the accessibility of this technique to more surgeons and patients.